Anti-neovasculature preparations for cancer

Details Anti-neovasculature preparations for cancer Anti-neovasculature preparations for cancer

2007-08-07

2007-08-07

Helms, Larry R. (Department: 1643)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S009100, C424S009200, C435S069100, C435S070100, C435S183000, C530S350000, C530S380000, C530S385000, C530S387100, C530S387300

Reexamination Certificate

active

10094699

ABSTRACT:
Disclosed herein are immunogenic compositions, methods of designing immunogenic compositions, methods of treatment using immunogenic compositions, methods of evaluating cell-mediated immunity resulting from immunogenic compositions, research models, and methods of making research models, all of which relate to targeting tumor vasculature.

REFERENCES:
patent: WO 99/43801 (1999-09-01), None
patent: WO 00/06723 (2000-02-01), None
patent: WO 01/82963 (2001-11-01), None
Verma et al. (1997) Nature vol. 389, p. 239-242.
Marshall (1995) Science, vol. 269, p. 1050-1055.
Eck et al. (Goodman & Gilman's The Pharmacological Basis of Therapeutics (1996), 9th Edition, Chapter 5, McGraw-Hill, NY).
Ross et al, Human Gene Therapy, 1996, vol. 7, pp. 1781-1790.
Rubanyi, Mol. Aspects Med. (2001) 22:113-142.
Juengst British Medical Journal (2003) vol. 326, pp. 1410-1411.
Ratnov et al (Gene Therapy 2000, 7:1853-1858).
Borges et al (Current Opinion in Gastroenterology 2002, 18(6): 723-731).
Shaw and Strong (Frontiers in Bioscience 11, 1189-1198, Jan. 1, 2006).
Feltquate et al (J Immunology 1997 158:2278-2284).
Pertmer et al (J. Virology, 1996 70:6119-6125).
Barry et al (Vaccine 1997 15:788-791).
Seppa. Science News Online (Aug. 8, 1998): http://www.sciencenews.org/pages/sn—arc98/8—8—98/fob3.htm.
Drug Discovery and Development (http://www.dddmag.com/Glossary.aspx?RPTID=KWSRCH&SEARCHWORD=vaccine&SEARCHMETHOD=WORD).
Davidoff et al (Journal of Pediatric Surgery. Jan. 2001. 36:30-36).
Drabner and Guzman (Biomolecular Engineering. 2001. 17:75-82; Available online Feb. 15, 2001).
Fomsgaard et al (Vaccine. 1999. 18:681-691).
Millauer et al. 1994. Nature, 367:576-579.
Stratmann et al 1997. Anti-angiogenic gene therapy of malignant glioma, S68:105-110.
Machein et al. 1999. Human Gene Therapy, 10:1117-1128.
Millauer et al. 1996. Cancer Research, 1996. 56:1615-1620.
Rockwell and Goldstein (Molecular and Cellular Differentiation. 1995, 3:315-335).
Siemeister et al (Center and Metastasis Reviews.1998. 17:241-248).
Prewett et al (Cancer Research. 1999. 59:5209-5218).
Supplementary Search Report for International Patent Application No. 02715085.3 issued Oct. 5, 2004 by the European Patent Office.
Bellone, et al. “Cancer immunotherapy: synthetic and natural peptides in the balance.”Immunology Today. 20 (10): 457-462 (1999).
Brekken, et al. “Vascular Endothelial Growth Factor and Vascular Targeting of Solid Tumors.”Anticancer Research. 21(6B): 4221-4230 (2001).
Dias, et al. “Inhibition of both autocrine and paracrine VEGF/VEGFR-2 angiogenic pathways is essential to induce long term remission of human leukemias xenotransplanted into NOD-SCID mice.” Database Biosis Online! (2000) XP002288727 (abstract).
Lorber, et al. “Human Allogeneic Vascular Rejection After Arterial Transplantation and Peripheral Lymphoid Reconstitution in Severe Combined Immunodeficient Mice.” Transplantation. 67(6): 897-903 (1999).
Marchand, et al. “Blockade of in vivo VEGF-mediated angiogenesis by antisense gene therapy: role of Flk-1 receptors.”Am J Physiol Heart Circ Physiol. 282:H194-H204 (2002).
Murray, et al. “Human T-cell mediated destruction of allogeneic dermal microvessels in a severe combined immunodeficient mouse.”Proc. Natl. Acad. Sci. 91(19): 9146-9150 (1994).
Nor, et al. “Engineering and Characterization of Functional Human Microvessels in Immunodeficient Mice.”Laboratory Investigation. 81(4): 453-463 (2001).
Parast, et al. “Characterization and Kinetic Mechanism of Catalytic Domain of Human Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase (VEGFR2 TK), a Key Enzyme in Angiogenesis.”Biochemistry. 37: 16788-16801 (1998).
Shiroki, et al. “Human Peripheral Blood Leukocyte-Reconstituted Severe Combined Immunodeficient Mouse: Analysis of human immune response against porcine islet transplantation.”Transplantation. 63(6): 818-823 (1997).
Tary-Lehmann, et al. “The human immune system in hu-PBL-SCID mice.”Immunology Today. 16(11): 529-533 (1995).
Tereb, et al. “Human T Cells Infiltrate and Injure Pig Coronary Artery Grafts with Activated but not Quiescent Endothelium in Immunodeficient Mouse Hosts.”Transplantation. 71(11): 1622-1630 (2001).
Kershaw et al., “Generation of Gene-Modified T Cells Reactive Against the Angiogenic Kinase Insert Domain-Containing Receptor (KDR) Found on Tumor Vasculature”, Human Gene Therapy, 11: 2445-2452 (2000).
Gong, M., et al., “In vivo eradication of prostate cancer tumors in SCID mice using genetically modified human T cells targeted to PSMA,” J. Urol., Apr. 2000, vol. 163, No. 4 Suppl., p. 36, abstract #155.
Mincheff, M., et al., “Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial,” Eur. Urol., Aug. 2000, vol. 38, No. 2, pp. 208-217.
O'Connell, K., et al., “Endothelial cells transformed by SV40 T antigen cause Kaposi's sarcomalike tumors in nude mice,” Am. J. Pathol., Oct. 1991, vol. 139, No. 4, pp. 743-749.
Salgaller, M.L., et al., “Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA),” The Prostate, May 1998, vol. 35, No. 2, pp. 144-151.
Yang, J., et al., “Telomerized human microvasculature is functional in vivo,” Nat. Biotech., Mar. 1, 2001, vol. 19, No. 3, pp. 219-224.
U.S. Appl. No. 09/380,534, “A Method of Inducing at CTL Response,” filed Sep. 1, 1999.
U.S. Appl. No. 09/560,465, “Epitope Synchronization in Antigen Presenting Cells,” filed Apr. 28, 2000.
U.S. Appl. No. 09/561,074, “Method of Epitope Discovery,” filed Apr. 28, 2000.
U.S. Appl. No. 09/561,571, “Epitope Clusters,” filed Apr. 28, 2000.
U.S. Appl. No. 09/561,572, “Expression Vectors Encoding Epitopes or Target-Associated Antigens,” filed Apr. 28, 2000.
U.S. Appl. No. 09/776,232, “Method of Inducing a CTL Response,” filed Feb. 2, 2001.
U.S. Appl. No. 10/005,905, “Epitope Synchronization in Antigen Presenting Cells,” filed Nov. 7, 2001.
U.S. Appl. No. 10/026,066, “Epitope Synchronization in Antigen Presenting Cells,” filed Dec. 7, 2001.
U.S. Appl. No. 60/282,211, “Epitope Sequences,” filed Apr. 6, 2001.
U.S. Appl. No. 60/336,968, “Expression Vectors Encoding Epitopes of Target-Associated Antigens and Methods for Their Design,” filed Nov. 7, 2001.
U.S. Appl. No. 60/337,017, “Epitope Sequences,” filed Nov. 7, 2001.
U.S. Appl. No. 60/363,131, “HLA-Transgenic Murine Tumor Cell Line,” filed Mar. 7, 2002.
U.S. Appl. No. 60/363,210, “Epitope Sequences,” filed Mar. 7, 2002.
Borsi et al., “Differential Expression of the Fibronectin Isoform Containing the ED-B Oncofetal Domain in Normal Human Fibroblast Cell Lines Originating from Different Tissues, ”Experimental Cell Research199: 98-105 (1992).
Camemolla et al., “A Tumor-associated Fibronectin Isoform Generated by Alternative Splicing of Messenger RNA Precursors,”Eur. Mol. Biol. Organ. J. 6: 2337-2342 (1987).
Castellani et al., “The Angiogenesis Marker ED-B+ Fibronectin Isoform in Intracranial Meningiomas,”Acta Neurochir(Wien) 142: 277-282 (2000).
Castellani et al., “The Fibronectin Isoform Containing the ED-B Oncofetal Domain: A Marker of Angiogenesis,”Int. J. Cancer59: 612-618 (1994).
Chang et al., “Five Different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-associated Neovasculature,”Cancer Research59: 3192-3198 (1999).
Chang et al., “Prostate-specific Membrane Antigen is produced in Tumor-associated Neovasculature,”Clinical Cancer Research5: 2674-2681 (1999).
Chang et al., “Mosaic blood vessels in tumors: Frequency of c

Affiliated with

Also associated with

Rating

Anti-neovasculature preparations for cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-neovasculature preparations for cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-neovasculature preparations for cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3851083